๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Acute myelogenous leukemia following complete remission of small cell carcinoma of the lung

โœ Scribed by Yu, Peter P. ;Waxman, Jenny S. ;Chahinian, A. Philippe ;Efremidis, Anna P. ;Holland, James F.


Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
322 KB
Volume
14
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

โœฆ Synopsis


The treatment of patients with small cell carcinoma of the lung (SCCL) with combination chemotherapy and radiation has dramatically improved survival in the past decade. With this increased survival, long term complications of therapy are becoming apparent. We report a patient who died of acute myelogenous leukemia (AML) while in complete remission from SCCL. Review of the literature indicates that there may be an increased incidence of AML following successful induction of complete remission in patients with SCCL.


๐Ÿ“œ SIMILAR VOLUMES


Relapse rates following cessation of che
โœ Baum, E. ;Sather, H. ;Nachman, J. ;Seinfeld, J. ;Krivit, W. ;Leikin, S. ;Miller, ๐Ÿ“‚ Article ๐Ÿ“… 1979 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 494 KB

The therapeutic benefit of maintenance chemotherapy beyond three years for children with acute lymphocytic leukemia (ALL) in continuous complete remission was evaluated by the investigators of Childrens Cancer Study Group (CCSG). Two hundred and twenty leukemic children in first remission for three

A pilot study of interleukin-2 for adult
โœ Jorge E. Cortes; Hagop M. Kantarjian; Susan O'Brien; Francis Giles; Michael J. K ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 2 views

## BACKGROUND. Interleukin-2 (IL-2) has immunomodulatory effects, including stimulating the activity of cytotoxic T cells and natural killer cells, and inducing the generation of lymphokine-activated killer cells. The authors investigated whether IL-2 may improve the duration of complete remission